BioSpace News Archive

Acurx Pharmaceuticals, Inc. announced today that David P. Luci , President & CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

Kane Biotech Inc. will announce its second quarter 2023 financial results after market close on Tuesday, August 29, 2023.

Foundery, a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced an initial closing of its inaugural fund, Foundery I, LP, with total capital commitments and contributed assets as of the closing equal to $29.6 million.

UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research.

Wenzel Spine, Inc. is pleased to announce the recent FDA clearance for their primaLOK SP System.

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured revolving credit agreement with J.P. Morgan.

Nascent Biotech, Inc. announced today that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer.

Akava Therapeutics, Inc. announced On July 3rd, the U.S. Food and Drug Administration cleared Akava’s Investigational New Drug (IND) application for the treatment of amyotrophic lateral sclerosis (ALS) to proceed with a Phase I first-in-human study in healthy subjects using Akava’s investigational new drug, AKV9 (formerly NU-9).

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer.